-
Angiotensin II: From Receptor Signal to Translation
2026-09-30
Angiotensin II is more than a vasopressor challenge: it is a controllable mechanistic lever for connecting GPCR signaling, oxidative stress, endothelial dysfunction, vascular smooth muscle cell hypertrophy, and disease-model endpoints. This thought-leadership guide shows translational researchers how to use Angiotensin II strategically, interpret pathway-specific readouts, and design experiments that move beyond routine product-page claims.
-
ALDH2 Activation Delays Pressure-Overload Heart Failure
2026-09-29
A 2025 Experimental Cell Research study identifies ALDH2 activation as a strategy for extending cardiomyocyte proliferation during early postnatal development and delaying pressure overload-induced heart failure in adult mice. Its findings connect aldehyde metabolism and redox control with cardiac cell-cycle regulation, while leaving important questions about mechanism, dosing, and relevance to human disease.
-
Microfluidic Peptide/RNA Complexes for Pulmonary Delivery
2026-09-29
This 2025 study shows that microfluidically prepared complexes of siRNA or mRNA with cationic peptides can be aerosolised using a vibrating mesh nebuliser while retaining RNA binding and in vitro transfection performance. The work provides a practical framework for evaluating formulation robustness under pulmonary delivery stresses, although its evidence remains limited to aerosol and cell-based testing.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-28
Montes-Worboys and colleagues tested whether monocyte-derived dendritic cells could carry active amikacin into Mycobacterium avium granulomas in mice. Their findings support cell-mediated, site-directed drug delivery as a research strategy, while leaving therapeutic efficacy, dosing, and clinical applicability to be established.
-
Streptavidin-FITC for Biotin Detection in LNP Studies
2026-09-27
Use Streptavidin-FITC to visualize biotinylated probes, antibodies, or carefully validated tracer cargo alongside functional lipid nanoparticle (LNP) assays. The workflow connects fluorescence-based localization with recent findings on LNP surface charge and cell V-ATPase activity—while clarifying why a fluorescent signal alone does not prove functional delivery.
-
Sulfaphenazole Restores Vasodilation in Diabetic Mice
2026-09-26
In db/db mice, eight weeks of Sulfaphenazole treatment restored acetylcholine-dependent vasodilation while lowering a plasma oxidative-stress marker and increasing plasma nitrite, without changing glucose levels. The study positions CYP2C inhibition as a candidate mechanism in diabetic vascular dysfunction, while leaving the precise enzyme, tissue-level causal pathway, and relevance to human disease unresolved.
-
Azilsartan (TAK-536) for Reproducible AT1 Studies
2026-09-26
A practical guide to using Azilsartan (TAK-536; SKU B2210) in cell-based AT1 receptor, renin–angiotensin system, and neuroinflammation research. It connects published astrocyte–microglia findings with careful stock preparation, viability-assay controls, data interpretation, and product-selection criteria.
-
CK2 and ERK8 Inhibitor in Condensate Assays
2026-09-25
Explore how the small molecule inhibitor 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid can support kinase-focused assay design. This article connects kinase perturbation to condensate research while distinguishing testable hypotheses from findings established for SARS-CoV-2 nucleocapsid.
-
Cathepsin B Inhibition: From Mechanism to Translation
2026-09-25
A translational framework for using CA-074 to test cathepsin B biology—connecting enzyme selectivity, model choice, orthogonal validation, and the limits of moving evidence across species and disease contexts.
-
Adamtsl3 Controls PNN Integrity and Adult Plasticity
2026-09-24
The study identifies Adamtsl3 as a parvalbumin-interneuron-associated regulator of perineuronal nets, acting in part through MMP9 to preserve extracellular-matrix integrity. Genetic deletion and pharmacological rescue experiments connect PNN loss with altered Otx2 uptake, oxidative stress, and the re-emergence of juvenile-like ocular dominance plasticity in adults.
-
Gap26 in 3D Osteocyte Mechanotransduction
2026-09-24
Explore how Gap26, a connexin 43 mimetic peptide, could help dissect calcium-wave propagation in mechanically stimulated 3D osteocyte networks. A close reading of the PUFFS microfluidic study shows how to design informative perturbation experiments—and where Gap26’s dual channel effects limit interpretation.
-
Deracoxib: Selective COX-2 Inhibitor Research Guide
2026-09-23
Deracoxib is a selective COX-2 inhibitor used in veterinary pain, inflammation, and canine cancer biology research. Evidence supports concentration-dependent cytotoxicity in canine tumor-cell models, but in vitro findings should not be interpreted as proof of clinical anticancer efficacy.
-
ABT-888 (Veliparib) in DNA Repair Research
2026-09-22
ABT-888, also called Veliparib, is a selective PARP1 and PARP2 inhibitor used to study DNA repair inhibition and chemotherapy sensitization. Preclinical evidence supports its use with DNA-damaging agents and radiation, while MSI status and PARP-resistance biology require model-specific validation.
-
Nigericin sodium salt: Practical Workflow Guide
2026-09-22
Nigericin sodium salt is a potassium ionophore for controlled studies of ion transport across biological membranes, cytoplasmic pH regulation, platelet aggregation modulation, and lead (Pb2+) ion transport. This guide translates the product dossier into handling, assay setup, and quality-control steps while defining boundaries for research use; it should not be used to support clinical treatment, diagnosis, or unsupported mechanistic conclusions.
-
Mitofusin 2, Angiotensin II, and Vascular Aging
2026-09-21
The 2024 iScience study identifies an Angiotensin II–STAT3–BCL6 pathway that suppresses MFN2 and promotes mitochondrial dysfunction in senescent endothelial cells. By combining human endothelial-cell perturbation experiments with mouse vascular validation, the work positions MFN2 as a mechanistic link between renin–angiotensin signaling, mitochondrial injury, and vascular aging.